

16 January, 2018

To,
The Assistant Vice President,
Surveillance Department,
The National Stock Exchange of India Ltd
Exchange Plaza, Bandra Kurla Complex
Mumbai - 400 051

Dear Sir,

Sub: - Reply to your letter on increase in volume.

Ref:- Your letter no. NSE/CM/Surveillance/ 7295 dated January 15, 2018.

Reference the above, this is to inform you that in compliance of regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 the Company has been regularly making disclosure of all material developments as and when these take place.

As informed vide our letter dated September 05, 2017, the Merck KGaA, Germany, the ultimate holding Company of the Company has announced that it is preparing for strategic options for its Consumer health business globally including a potential full or partial sale of the business as well as partnerships. This strategic initiative would involve the Company's consumer health business in India as well, the implementation of potential measures and their specific design are subject to further analysis and decision making by competent bodies.

After the above announcement there is no further development on the above subject.

Additionally, we would like to bring to your notice that the Company is keeping its trading window closed for the concerned connected persons. This is being informed to the stock exchange from time to time.

Except the above we are not having knowledge of any other material information which may have impact on the price and volume of trading of the Company shares on the exchanges.

Thanking you,

Yours faithfully,
For Merck Limited



Vikas R. Gupta
General Counsel & Company Secretary



Merck Limited

Registered Office
Godrej One, 8th Floor, Pirojshanagar
Eastern Express Highway, Vikhroli East
Mumbai 400079, India.
Phone +91 22 62109000
Fax +91 22 62109999
www.merck.co.in
CIN: L99999MH1967PLC013726